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The antigens associated with the MNS blood group system (ISBT 
002) are located on glycophorin A (GPA) and glycophorin B (GPB). 
The most frequently encountered antibodies to antigens in this 
system by a transfusion medicine service are those directed 
against M, N, S, and s. Individuals lacking GPA typically have 
red blood cells that lack M, N, and Ena, whereas those lacking 
both GPA and GPB lack M, N, and Ena as well as S, s, and U. 
Such individuals may develop a rare antibody, anti-Ena, directed 
against determinants on GPA. This antibody is capable of causing 
hemolytic transfusion reactions and hemolytic disease of the 
fetus and newborn. This case report describes a pregnant woman 
found to have anti-Ena. Molecular testing supported an Mk 
phenotype that was found in several members of her immediate 
family. Immunohematology 2019;35:159–161.
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Introduction
The MNS blood group system (ISBT 002) consists of red 
blood cell (RBC) antigens located on glycophorin A (GPA) and 
glycophorin B (GPB). The GYPA and GYPB genes encoding these 
glycophorins are located on the long arm of chromosome 4.1,2 
The most frequently encountered antibodies to antigens in this 
system by a transfusion medicine service are those directed 
against M, N, S, and s. In rare cases, individuals may lack GPA 
or both GPA and GPB on their RBCs because of gene deletion, 
and such individuals may develop a rare antibody, anti-Ena, 
to determinants located on GPA. Anti-Ena does not target a 
precise antigen on GPA but rather is an “umbrella” term for 
antibodies directed at external regions of GPA made by rare 
people who lack all or part of GPA. Three broad categories of 
anti-Ena have been defined according to the effect of protease 
enzymes on the antigenic determinants that each detects, 
namely anti-EnaTS, -EnaFS, and -EnaFR.3 The results from 
a previous study by Tanner and Anstee4 showed that RBCs 
lacking GPA, the major sialoglycoprotein on the RBC surface, 
lack Ena. This deficiency reduces the overall zeta potential of 
an intact RBC resulting in RBCs with a higher propensity to 
agglutinate than RBCs expressing GPA.4 Antibodies against 
Ena have been associated with hemolytic transfusion reactions 
and hemolytic disease of the fetus and newborn (HDFN).5 
We present a case of the rare Mk phenotype with allo-anti-
Ena in a maternal prenatal sample. We discuss the clinical 
ramifications of this finding.
Case Report
A 28-year-old Caucasian woman, never transfused, 
primigravida at approximately 23 weeks’ gestation, presented 
for routine prenatal care at her local community hospital. A 
routine type and antibody detection test was performed and 
found to be positive, and her sample was flagged for further 
testing by the Immunohematology Reference Laboratory 
(IRL) at Miller-Keystone Blood Center (Bethlehem, PA). The 
IRL identified anti-Ena by indirect antiglobulin testing. The 
presence of this antibody is worrisome for both mother and 
fetus because anti-Ena of an IgG isotype has been implicated 
in both acute and delayed hemolytic transfusion reactions 
and HDFN.3 The patient was referred to the Maternal Fetal 
Medicine department at Penn State Hershey Medical Center 
(Hershey, PA). 
The initial antibody detection test performed at Hershey 
Medical Center demonstrated weak positive reactivity with all 
three reagent screening RBCs and with 11 of 11 panel RBCs at 
the antiglobulin phase using a solid-phase red cell adherence 
assay. The direct antiglobulin test was negative. Further 
testing by our IRL revealed that the patient’s RBCs typed 
M–N–S–s– with licensed RBC antisera (Immucor, Norcross, 
GA). This finding prompted further testing of the patient’s 
plasma against a U– and a U+var reagent RBC, both of which 
were reactive. This reactivity was not detected when the RBCs 
were treated with ficin. 
These results, together with the patient’s non-African 
ethnicity, allowed the IRL to rule out anti-U and anti-Wrb. 
Classically, it was expected that both of these antibodies would 
remain reactive with ficin-treated reagent RBCs. Furthermore, 
the testing of the patient’s plasma aginast ficin-treated reagent 
RBCs in low-ionic-strength solution (tube method) resulted in 
no agglutination. These findings are consistent with a subtype 
of Ena that is sensitive to ficin treatment, historically known 
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as EnaFS. However, because of the lack of MkMk or En(a–) 
reagent RBCs available for testing against the patient’s plasma, 
these findings were not confirmed. 
IgG titers were then performed without enhancement 
media at 37°C for 60 minutes. The initial titer was 1, and 1 
month later, the titer was 2; these results are within procedural 
variation and the titer difference was considered insignificant 
by the IRL. The sample was referred to the National Molecular 
Laboratory at the American Red Cross (Philadelphia, PA) 
for performance of RBC genotyping by PreciseType HEA 
Molecular BeadChip (Immucor). This molecular platform 
interrogates targets to predict expression of M, N, S, s, and 
U. The patient sample failed to amplify for all the assays that 
interrogate GYPA and GYPB targets. RBCs from the presumed 
father of the fetus demonstrated an M+N–S+s+ phenotype by 
serological and molecular methods from the same laboratories 
as the patient. The patient’s molecular and serologic findings 
from testing of the patient’s sample were consistent with an 
Mk phenotype, which is a null phenotype for antigens on both 
GPA and GPB, encoded by homozygosity for GYP*01N. No 
typing of the patient’s RBCs with antisera against other high-
prevalence antigens in the MNS system was performed.
Given the exceedingly rare occurrence of En(a–) 
individuals (<0.1%), clinical encounters with alloantibodies to 
Ena are limited. If transfusions were required for the mother 
or fetus, our options were autologous donations, directed 
donations from family members who match the patient’s 
phenotype, or via rare blood donor registries. Fortunately, this 
patient came from a large family, most of whom were tested 
both serologically and molecularly. A blood group genotyping 
platform (ID CORE XT; Grifols, Barcelona, Spain) that also 
interrogates GYPA and GYPB targets to predict the common 
antigens in the MNS system was used to analyze samples from 
the family members at Grifols laboratory. Four siblings were 
predicted to express the same Mk phenotype as the patient. 
These results were confirmed, also by Grifols laboratory, by 
allele-specific polymerase chain reaction (PCR) and agarose 
gel electrophoresis, which showed an absence of products 
for GYPA exons 2–7; GYPB exons 1–2 and 4–6; and GYPB 
pseudo-exon 3 (data not shown). A pedigree demonstrates 
the likely inheritance pattern of the GYPA and GYPB genes 
and the MNS antigens (Fig. 1). Given the rarity in the general 
population and prevalence within this family, we can postulate 
that Mk phenotype inheritance is due to consanguinity among 
the parents in the pedigree, although an inquiry to confirm 
this was not pursued. 
The patient’s antibody titers remained unchanged 
throughout her pregnancy (minimum 1; maximum 2), with 
low reactivity in a mononuclear monolayer assay (MMA) 
performed by Grifols laboratory. The MMA is used to predict 
an antibody’s ability to promote macrophagocytic adherence 
and phagocytosis upon exposure to a cognate antigen with or 
without a source of complement.
The consensus in this case was to manage this as a high-
risk pregnancy with frequent intensive monitoring, including 
antibody titers. At term, the patient underwent induction of 
labor and successfully delivered a healthy baby boy by vaginal 
route. The delivery was without event, no transfusions were 
necessary antepartum or postpartum, and a neonatal sample 
revealed no bound RBC antibodies (i.e., negative direct 
antiglobulin test) or evidence of hemolysis.
Fig. 1 This pedigree describes the inheritance of the GYPA and GYPB alleles and expression of these antigens within the MNS blood group 
system. Arrow notes the predicted phenotype of the proposita.
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Discussion
Because Ena is a high-prevalence antigen, there are 
few case reports of anti-Ena. This rarity affords the medical 
community limited data about the potential clinical sequelae 
of this antibody, which is concerning in a pregnant woman. 
The identification of the antibody resulted in this case being 
monitored as a high-risk pregnancy, based on previous 
case reports.6 Providing this patient with rare En(a–) RBCs 
(or MkMk RBCs) via national or international blood donor 
registries would have been exceedingly difficult. Donors in a 
registry do not guarantee that RBC units of a desired phenotype 
will be available when needed. Autologous donation was also 
considered for the purposes of antepartum or postpartum 
use as well as future use, if needed, in the form of frozen 
RBCs. The allogenic donor registry and autologous donation 
approaches were discussed and understood by the patient. 
These approaches were unnecessary, however, because the 
patient had many compatible family members available and 
willing to donate blood by directed allogenic donations.
The Mk phenotype within this family is due to deletions 
involving exons 2–7 of the GYPA and exons/pseudo-exon 1–6 
of the GYPB genes rather than a mutation in both the GYPA 
and GYPB genes.7 This genetic alteration results in the absence 
of GPA, GPB, and the constitutive antigens of the MNS blood 
group system. We surmise that our patient was exposed to the 
Ena present on the GPA of her baby’s RBCs in utero, or perhaps 
during an undetected miscarriage, which led to a subsequent 
alloimmunization. However, given the infrequency in which 
fetal antigens contact the maternal immune system and the 
low titer of the maternal antibody, there is a possibility that 
the anti-Ena may have been non-RBC related (“naturally-
occurring”).
In conclusion, this case report describes the identification 
of a rare anti-Ena in a prenatal patient and the subsequent 
testing of family members in preparation for the delivery. The 
clinical finding of a rare antibody for which there are limited 
data requires leveraging every resource available to predict its 
behavior and provide safe blood products to patients who may 
require transfusion.
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